Boston Scientific Adds More Non-Vascular Stents To MedSurg Business With MI Tech Acquisition
Executive Summary
Boston Scientific will pay about $230m for 64% of Korea-based MI Tech, which developed the Hanarostent line of conformable, self-expanding metal stents for endoscopic and urologic applications.
You may also be interested in...
Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
Boston Scientific Picks Up Pancreatic Stent Maker Xlumena
In the $62.5 million-plus-milestone deal Boston Scientific gets Xlumena's Axios and Hot Axios stent and delivery systems for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts. The products fit alongside Boston's Expect endoscopic ultrasound aspiration needles.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.